[HTML][HTML] Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial
KC Herold, SE Gitelman, SM Willi, PA Gottlieb… - Diabetologia, 2013 - Springer
Aims/hypothesis Type 1 diabetes results from a chronic autoimmune process continuing for
years after presentation. We tested whether treatment with teplizumab (a Fc receptor non …
years after presentation. We tested whether treatment with teplizumab (a Fc receptor non …
[PDF][PDF] Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial
KC Herold, SE Gitelman, SM Willi, PA Gottlieb… - Diabetologia, 2013 - researchgate.net
Aims/hypothesis Type 1 diabetes results from a chronic autoimmune process continuing for
years after presentation. We tested whether treatment with teplizumab (a Fc receptor non …
years after presentation. We tested whether treatment with teplizumab (a Fc receptor non …
[PDF][PDF] Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial
KC Herold, SE Gitelman, SM Willi, PA Gottlieb… - Diabetologia, 2013 - academia.edu
Aims/hypothesis Type 1 diabetes results from a chronic autoimmune process continuing for
years after presentation. We tested whether treatment with teplizumab (a Fc receptor non …
years after presentation. We tested whether treatment with teplizumab (a Fc receptor non …
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.
KC Herold, SE Gitelman, SM Willi, PA Gottlieb… - Diabetologia, 2012 - europepmc.org
Methods In a randomised placebo-controlled trial we treated 58 participants with type 1
diabetes for 4-12 months with teplizumab or placebo at four academic centres in the USA. A …
diabetes for 4-12 months with teplizumab or placebo at four academic centres in the USA. A …
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial
KC Herold, SE Gitelman, SM Willi, PA Gottlieb… - Diabetologia, 2013 - hero.epa.gov
AIMS/HYPOTHESIS: Type 1 diabetes results from a chronic autoimmune process continuing
for years after presentation. We tested whether treatment with teplizumab (a Fc receptor non …
for years after presentation. We tested whether treatment with teplizumab (a Fc receptor non …
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial
KC Herold, SE Gitelman, SM Willi, PA Gottlieb… - Diabetologia, 2013 - escholarship.org
Aims/hypothesisType 1 diabetes results from a chronic autoimmune process continuing for
years after presentation. We tested whether treatment with teplizumab (a Fc receptor non …
years after presentation. We tested whether treatment with teplizumab (a Fc receptor non …
[引用][C] Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial
KC HEROLD, SE GITELMAN… - Diabetologia …, 2013 - pascal-francis.inist.fr
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after
the new-onset period: a randomised controlled trial CNRS Inist Pascal-Francis CNRS Pascal and …
the new-onset period: a randomised controlled trial CNRS Inist Pascal-Francis CNRS Pascal and …
[HTML][HTML] Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial
KC Herold, SE Gitelman, SM Willi, PA Gottlieb… - Diabetologia, 2013 - ncbi.nlm.nih.gov
Methods In a randomised placebo-controlled trial we treated 58 participants with type 1
diabetes for 4–12 months with teplizumab or placebo at four academic centres in the USA. A …
diabetes for 4–12 months with teplizumab or placebo at four academic centres in the USA. A …
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial
KC Herold, SE Gitelman, SM Willi, PA Gottlieb… - 2013 - pubmed.ncbi.nlm.nih.gov
Aims/hypothesis Type 1 diabetes results from a chronic autoimmune process continuing for
years after presentation. We tested whether treatment with teplizumab (a Fc receptor non …
years after presentation. We tested whether treatment with teplizumab (a Fc receptor non …
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial
KC Herold, SE Gitelman, SM Willi, PA Gottlieb… - …, 2013 - search.proquest.com
Type 1 diabetes results from a chronic autoimmune process continuing for years after
presentation. We tested whether treatment with teplizumab (a Fc receptor non-binding anti …
presentation. We tested whether treatment with teplizumab (a Fc receptor non-binding anti …